Login
$GALT
$3.02 -$0.03 (0.98%) Live

$GALT SEC Filings

Filed On Filing
16 Nov 2026 8-K: Results of Operations and Financial Condition

Date of Report (Date of earliest event reported): November 16, 2026

16 Nov 2026 10-Q
13 Oct 2026 ARS
13 Oct 2026 DEFA14A
13 Oct 2026 Proxy statement: annual meeting on December 3, 2026
02 Oct 2026 PRE 14A
14 Aug 2026 8-K: Results of Operations and Financial Condition

NORCROSS, Ga., August 14, 2026 (GLOBE NEWSWIRE) – Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the th...

14 Aug 2026 10-Q
04 Aug 2026 SCHEDULE 13D/A
04 Aug 2026 Form 4: Uihlein Richard E, Director

Received 34,376,167 shares by exercise or conversion ($106M)

04 Aug 2026 8-K: Unregistered Sales of Equity Securities

Chairman Richard E. Uihlein converts outstanding notes under five line of credit facilities into common stock

16 Jul 2026 Form 4: Jamil Khurram, Chief Medical Officer

Received 16,250 shares by exercise or conversion ($49.4K) · Sold 16,250 shares ($83.3K)

30 Jun 2026 Form 4: Shlevin Harold H., Director

Received 7,732 shares by exercise or conversion ($9.51K) · Sold 7,732 shares ($38.7K) · Received 22,268 shares by exercise or conversion ($27.4K) · 1 more

30 Jun 2026 Form 4: Jamil Khurram, Chief Medical Officer

Received 4,570 shares by exercise or conversion ($10.8K) · Sold 4,570 shares ($22.9K) · Received 47,467 shares by exercise or conversion ($119K) · 1 more

29 Jun 2026 144
26 Jun 2026 144
26 Jun 2026 144
25 Jun 2026 Form 4: Jamil Khurram, Chief Medical Officer

Received 7,557 shares by exercise or conversion ($9.3K) · Sold 7,557 shares ($23.7K)

23 Jun 2026 144
23 Jun 2026 8-K: Regulation FD Disclosure

Galectin Therapeutics Announces Positive Type C Meeting with the FDA for Belapectin in Patients with MASH Cirrhosis and Portal Hypertension

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support